Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02774421 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
A Phase 1 study of Posterior Fossa Ependymoma (PFEPN), sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT02774421 is a Phase 1 study of Posterior Fossa Ependymoma (PFEPN) that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02774421, a Phase 1 study of Posterior Fossa Ependymoma (PFEPN), is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intrathecal trastuzumab in combination with subcutaneous (subQ) Granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with relapsed PFEPN
Conditions Studied
Interventions
- DRUG Trastuzumab after SubQ GM-CSF
- DRUG Trastuzumab in combination with SubQ GM-CSF
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02774421
The ClinicalTrials.gov registry entry for NCT02774421 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Posterior Fossa Ependymoma (PFEPN) appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab after SubQ GM-CSF is the first listed.
NCT02774421 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT02774421 about?
NCT02774421 is a clinical study titled "Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma". This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intrathecal trastuzumab in combination with subcutaneous (subQ)...
What is the current status of trial NCT02774421?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-06-12. Estimated completion is 2026-03.
What conditions does trial NCT02774421 study?
This clinical trial studies the following conditions: Posterior Fossa Ependymoma (PFEPN).
What interventions are being tested in trial NCT02774421?
The interventions under investigation include: Trastuzumab after SubQ GM-CSF (DRUG), Trastuzumab in combination with SubQ GM-CSF (DRUG).
Who is sponsoring clinical trial NCT02774421?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02774421 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.